Abstract

Andexanet substantially reduces anti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitors.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call